GLSI logo

Greenwich LifeSciences Inc. (GLSI)

$18.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GLSI

Market cap

$274482490

EPS

-1.64

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.56212

Price on GLSI

Previous close

$13.76

Today's open

$16.06

Day's range

$15.73 - $19.28

52 week range

$7.78 - $34.10

Profile about GLSI

CEO

Snehal S. Patel

Employees

7

Headquarters

Stafford, TX

Exchange

NASDAQ Capital Market

Shares outstanding

14678208

Issue type

Common Stock

GLSI industries and sectors

Healthcare

Biotechnology & Life Sciences

News on GLSI

Greenwich LifeSciences: Buy Due To GLSI-100 BC Population Expansion And More

I maintain a Buy rating on Greenwich LifeSciences, Inc., as phase 3 expansion and encouraging GLSI-100 data support its HER2-positive breast cancer opportunity. GLSI's open-label study showed a 70%–80% recurrence reduction in 250 non-HLA-A*02 patients, supporting U.S. and European trial expansion into this population. Two GLSI abstracts and corresponding posters at SABCS, December 8–11, 2026, provide a near-term catalyst; randomized phase 3 efficacy remains unproven.

news source

Seeking Alpha • an hour ago

news preview

Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations.

news source

GlobeNewsWire • Nov 17, 2026

news preview

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

news source

Market Watch • Aug 27, 2026

news preview

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.

news source

GlobeNewsWire • Aug 10, 2026

news preview

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.

news source

GlobeNewsWire • Jul 22, 2026

news preview

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.

news source

GlobeNewsWire • Jul 20, 2026

news preview

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.

news source

GlobeNewsWire • Jul 16, 2026

news preview

Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer.

news source

Seeking Alpha • Jul 16, 2026

news preview

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.

news source

GlobeNewsWire • Jul 9, 2026

news preview

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

news source

GlobeNewsWire • Jun 1, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Greenwich LifeSciences Inc.

Open an M1 investment account to buy and sell Greenwich LifeSciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GLSI on M1